ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that ...

CHICAGO, IL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional ...

CENTERVILLE, Utah, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult a qualified healthcare ...

Nutriband Inc. has successfully completed the scale-up of the commercial manufacturing process for its lead product, Aversa™ Fentanyl, in partnership with Kindeva, a contract development and ...

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty pharmaceutical company, is pleased to announce ...

Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...

NEW YORK, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical or dermatological advice. Always consult a qualified ...

A bio-inspired dual-amplified patch (MN@EV/SC) was fabricated by integrating extracellular vesicle-loaded microneedles with a soft suction chamber for effective transdermal delivery. The MN@EV/SC ...

There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...